Healthy Volunteer Clinical Trial
Official title:
Calorie Restriction Intervention Induces Enterotype-associated BMI Loss in Nonobese Individuals
Calorie restriction (CR), which has the potential effect on weight loss and blood amino
acids, has been demonstrated to associate with gut microbiota in humans, especially in obese
individuals. However, studies for simultaneously evaluating enterotype-dependent impacts of
CR on the gut microbiota and blood amino acids in nonobese individuals are still limited.
Here, 41 nonobese individuals received a 3-week CR diet with approximately 50% fewer calories
than a normal diet. The investigators measured individuals' BMI and blood amino acid
concentration, along with the gut microbiota before and after the intervention. In this
trial, 28 Enterotype Bacteroides (ETB) subjects and 13 Enterotype Prevotella (ETP) subjects
were identified before the intervention.
The purpose of this intervention study is to evaluate the effect of calorie restriction on
BMI loss, amino acid, and gut microbiota in healthy volunteers of two different enterotypes
and provide useful insights for potential application of gut microbiome stratification in
personalized nutrition intervention.
1. Volunteer Recruitment
Volunteer-wanted posters were propagated at the China National Gene Bank in Shenzhen
from March to April 2017. A non-obese healthy volunteer was considered if his/her BMI
less than 28 kg/m2. 50 individuals met all the criteria and were recruited in this
study, and 41 individuals (24 females and 17 males aged 30 ± 6 years old) completed the
whole intervention. The study was approved by the institutional review board on
bioethics and biosafety of BGI-Shenzhen, Shenzhen (NO. BGI-IRB 17020). All participates
were fully informed of the design and purpose of this intervention study and signed a
written informed consent letter.
2. Experiment Process
The study included a one-week run-in period (baseline) and a three-week CR dietary
intervention period. During the first week (run-in period), all healthy volunteers
consumed their usual diet and were encouraged to avoid yogurt, high-fat foods, and
alcohol. The CR diet was comprised of ~50% calories of a normal-calorie diet (female,
1000kcal/day; male, 1200kcal/day). It was designed with carbohydrate, fat, and protein
as approximately 55%, 30% and 15% of the total energy intake respectively, according to
the Dietary Guidelines for Chinese Residents (2016) and nutritionally balanced and a
recent large nutritional study in China. Common foods in low-calorie diets such as rice,
vegetables, eggs, pork, and beef were prepared in the investigators' study center to
control experimental variables introduced by different foods and calorie estimation
errors.
Traditional Chinese cooking style - boiled, stir-fried and stewed, were applied for the
foods. For each meal, digital scales were used to measure the nutritional and caloric
values of different foods and total meal for males and females respectively.
3. Sample and Data Collection
BMI, blood and fecal samples of each volunteer were collected at the investigators' study
center at baseline and after the 3-week CR intervention. BMI was measured via the clinic
scale. The concentrations of 31 amino acids and derivatives in the fasting serum samples were
measured by LC-MS/MS. The gut microbial composition was determined using shotgun metagenomics
sequencing of fecal DNA.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
| Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
| Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
| Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
| Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
| Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
| Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
| Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01461967 -
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01579149 -
A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent
|
Phase 1 | |
| Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 |